<DOC>
	<DOCNO>NCT01753167</DOCNO>
	<brief_summary>This Phase II , randomize , double-blind , placebo-controlled study design ass safety clinical activity multiple intravenous dos MCMV5322A/MCMV3068A cytomegalovirus ( CMV ) -seronegative recipient renal transplant CMV-seropositive donor , use preemptive approach prevention CMV disease . Participants randomize two treatment group : active placebo control ; arm follow preemptively . The study plan enrollment approximately 120 participant ( 60 active 60 placebo ) .</brief_summary>
	<brief_title>A Study MCMV5322A/MCMV3068A Prevention Cytomegalovirus Disease High-Risk Kidney Allograft Recipients</brief_title>
	<detailed_description />
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<criteria>Participant schedule receive primary secondary renal allograft donor Participant seronegative CMV receiving allograft CMVseropositive donor Female participant childbearing age must negative pregnancy test result Day 1 , prior infusion For woman postmenopausal surgically sterile ( defined absence ovary and/or uterus ) : agreement remain completely abstinent use two method contraception time Participant suspect CMV disease Participant receive antiCMV therapy within 30 day prior screen ( exception use acyclovir , valacyclovir , famciclovir 10 day duration treatment acute herpes simplex herpes zoster participant receive acyclovir valacyclovir dose suppress herpes zoster ) Participants receive intravenous immunoglobulin ( IVIG ) within 3 month transplantation expectation receive IVIG time transplantation 3 month transplantation Participants receive B celldepleting therapy ( include limit rituximab ) within 3 month transplantation expectation receive therapy time transplantation 3 month transplantation Participant receive multiorgan transplant ( e.g. , liver pancreas addition kidney ) Active chronic hepatic hepatobiliary disease ( include know Gilbert 's syndrome ) elevation hepatic transaminase bilirubin &gt; = 2 time upper limit normal ( ULN ) Participant unlikely unwilling available followup full 24week duration study Female participant pregnant , plan become pregnant study , breastfeed History severe allergic , anaphylactic , hypersensitivity reaction chimeric humanize antibody fusion protein humanderived immunoglobulin preparation ; constituent MCMV5322A/MCMV3068A placebo Active treatment untreated tuberculosis infectious condition significant judgment investigator Infection hepatitis B , hepatitis C human immunodeficiency virus Previous exposure investigational agent within 12 week 5 halflives Any acute chronic condition , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition , opinion Principal Investigator , contraindicate use investigational drug may affect interpretation result render participant high risk treatment complication History alcoholism substance abuse within 6 month screen Participant expect require treatment prophylaxis antiviral antiCMV activity study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>